Solute carriers as drug targets: Current use, clinical trials and prospective

Molecular Aspects of Medicine

Volumn 34, Issue 2-3, 2013, Pages 702-710

  Rask Andersen, Mathias ^a   Masuram, Surendar ^a   Fredriksson, Robert ^a   Schiöth, Helgi B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Clinical trials; Drug target; SLC; Solute carrier; SSRI

Indexed keywords

BENDROFLUMETHIAZIDE; BRIVARACETAM; BUMETANIDE; CARIPORIDE; CARRIER PROTEINS AND BINDING PROTEINS; CHLOROTHIAZIDE; CLODRONIC ACID; DAPAGLIFLOZIN; ENIPORIDE; ETIRACETAM; FUROSEMIDE; HYDROFLUMETHIAZIDE; PROBENECID; PROTEIN SLC10A2; PROTEIN SLC12; PROTEIN SLC18; PROTEIN SLC2; PROTEIN SLC22; PROTEIN SLC25; PROTEIN SLC6; PROTEIN SLC7A5; PROTEIN SV2A; RESERPINE; SELETRACETAM; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; SOLUTE CARRIER; TETRABENAZINE; TIAGABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BLOOD GLUCOSE MONITORING; BONE METASTASIS; BRAIN EDEMA; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DRUG ACTIVITY; DRUG RESEARCH; DRUG TARGETING; DRUG TRANSPORT; EPILEPSY; GOUT; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFANTILE SPASM; MAJOR DEPRESSION; MENTAL DISEASE; MIGRAINE; MOLECULARLY TARGETED THERAPY; MOTOR DYSFUNCTION; MYOCLONUS EPILEPSY; OBSESSIVE COMPULSIVE DISORDER; OSTEOPOROSIS; PARKINSON DISEASE; PROTEIN FAMILY; PSYCHOSIS; REVIEW; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS;

EID: 84875137695     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2012.07.015     Document Type: Review

References (50)

1. T. Amann, and C. Hellerbrand GLUT1 as a therapeutic target in hepatocellular carcinoma Expert Opin. Ther. Targets 13 12 2009 1411 1427
2. + exchanger regulation for cardiac protection: a RSKy approach? Curr. Opin. Pharmacol. 8 2 2008 133 140
3. S.M. Bajjalieh, G.D. Frantz, J.M. Weimann, S.K. McConnell, and R.H. Scheller Differential expression of synaptic vesicle protein 2 (SV2) isoforms J. Neurosci. 14 9 1994 5223 5235
4. A. Balakrishnan, and J.E. Polli Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target Mol. Pharm. 3 3 2006 223 230
5. S.P. Berger, T.M. Winhusen, E.C. Somoza, J.M. Harrer, J.P. Mezinskis, D.B. Leiderman, M.A. Montgomery, R.J. Goldsmith, D.A. Bloch, B.M. Singal, and A. Elkashef A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence Addiction 100 Suppl 1 2005 58 67
6. F.I. Carroll, J.L. Howard, L.L. Howell, B.S. Fox, and M.J. Kuhar Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse AAPS J. 8 1 2006 E196 E203
7. E.C. Chao, and R.R. Henry SGLT2 inhibition- A novel strategy for diabetes treatment Nat. Rev. Drug Discov. 9 7 2010 551 559
8. W.D. Chey, M. Camilleri, L. Chang, L. Rikner, and H. Graffner A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation Am. J. Gastroenterol. 106 10 2011 1803 1812
9. K.M. Crowder, J.M. Gunther, T.A. Jones, B.D. Hale, H.Z. Zhang, M.R. Peterson, R.H. Scheller, C. Chavkin, and S.M. Bajjalieh Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) Proc. Natl. Acad. Sci. USA 96 26 1999 15268 15273
10. I.J. Diel, E.F. Solomayer, S.D. Costa, C. Gollan, R. Goerner, D. Wallwiener, M. Kaufmann, and G. Bastert Reduction in new metastases in breast cancer with adjuvant clodronate treatment N. Engl. J. Med. 339 6 1998 357 363
11. M. Dong, F. Yeh, W.H. Tepp, C. Dean, E.A. Johnson, R. Janz, and E.R. Chapman SV2 is the protein receptor for botulinum neurotoxin A Science 312 5773 2006 592 596
12. S.A. Eraly Organic anion transporter 3 inhibitors as potential novel antihypertensives Pharmacol. Res. 58 5-6 2008 257 261
13. S.A. Eraly, V. Vallon, D.A. Vaughn, J.A. Gangoiti, K. Richter, M. Nagle, J.C. Monte, T. Rieg, D.M. Truong, J.M. Long, B.A. Barshop, G. Kaler, and S.K. Nigam Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice J. Biol. Chem. 281 8 2006 5072 5083
14. R. Fredriksson, K.J. Nordstrom, O. Stephansson, M.G. Hagglund, and H.B. Schioth The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families FEBS Lett. 582 27 2008 3811 3816
15. B.C. Fuchs, and B.P. Bode Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin. Cancer Biol. 15 4 2005 254 266
16. S. Fulda, L. Galluzzi, and G. Kroemer Targeting mitochondria for cancer therapy Nat. Rev. Drug Discov. 9 6 2010 447 464
17. J. Geyer, T. Wilke, and E. Petzinger The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships Naunyn Schmiedebergs Arch Pharmacol. 372 6 2006 413 431
18. T.S. Guillot, and G.W. Miller Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons Mol. Neurobiol. 39 2 2009 149 170
19. T.S. Guillot, J.R. Richardson, M.Z. Wang, Y.J. Li, T.N. Taylor, B.J. Ciliax, O. Zachrisson, A. Mercer, and G.W. Miller PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity Neuropeptides 42 4 2008 423 434
20. M.G. Hagglund, S. Sreedharan, V.C. Nilsson, J.H. Shaik, I.M. Almkvist, S. Backlin, O. Wrange, and R. Fredriksson Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons J. Biol. Chem. 286 23 2011 20500 20511
21. S.R. Hansson, E. Mezey, and B.J. Hoffman Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. II. Expression in neural crest derivatives and their target sites in the rat Brain Res. Dev. Brain Res. 110 1 1998 159 174
22. - cotransport: the SLC12 family Pflugers Arch. 447 5 2004 580 593
23. M.A. Hediger, M.F. Romero, J.B. Peng, A. Rolfs, H. Takanaga, and E.A. Bruford The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction Pflugers Arch. 447 5 2004 465 468
24. P.J. Hoglund, K.J. Nordstrom, H.B. Schioth, and R. Fredriksson The solute carrier families have a remarkably long evolutionary history with the majority of the human families present before divergence of Bilaterian species Mol. Biol. Evol. 28 4 2011 1531 1541
25. J.A. Jacobsson, T. Haitina, J. Lindblom, and R. Fredriksson Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family Genomics 90 5 2007 595 609
26. J.A. Jacobsson, O. Stephansson, and R. Fredriksson C6ORF192 forms a unique evolutionary branch among solute carriers (SLC16, SLC17, and SLC18) and is abundantly expressed in several brain regions J. Mol. Neurosci. 41 2 2010 230 242
27. D. Jones Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor Nat. Rev. Drug Discov. 10 9 2011 645 646
28. K.T. Kahle, S.M. Barnett, K.C. Sassower, and K.J. Staley Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1 J. Child Neurol. 24 5 2009 572 576
29. K.T. Kahle, K.J. Staley, B.V. Nahed, G. Gamba, S.C. Hebert, R.P. Lifton, and D.B. Mount Roles of the cation-chloride cotransporters in neurological disease Nat. Clin. Pract. Neurol. 4 9 2008 490 503
30. R.M. Kaminski, M. Gillard, K. Leclercq, E. Hanon, G. Lorent, D. Dassesse, A. Matagne, and H. Klitgaard Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam Epilepsia 50 7 2009 1729 1740
31. A.S. Kristensen, J. Andersen, T.N. Jorgensen, L. Sorensen, J. Eriksen, C.J. Loland, K. Stromgaard, and U. Gether SLC6 neurotransmitter transporters: structure, function, and regulation Pharmacol. Rev. 63 3 2011 585 640
32. P.P. Lehenkari, M. Kellinsalmi, J.P. Napankangas, K.V. Ylitalo, J. Monkkonen, M.J. Rogers, A. Azhayev, H.K. Vaananen, and I.E. Hassinen Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite Mol. Pharmacol. 61 5 2002 1255 1262
33. F.W. Lohoff Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders Methods Mol. Biol. 637 2010 165 180
34. B.A. Lynch, N. Lambeng, K. Nocka, P. Kensel-Hammes, S.M. Bajjalieh, A. Matagne, and B. Fuks The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc. Natl. Acad. Sci. USA 101 26 2004 9861 9866
35. L. Mazur, M. Opydo-Chanek, and M. Stojak Glufosfamide as a new oxazaphosphorine anticancer agent Anticancer Drugs 22 6 2011 488 493
36. T. Nakanishi Drug transporters as targets for cancer chemotherapy Cancer Genomics Proteomics 4 3 2007 241 254
37. T. Nakanishi, and I. Tamai Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy J. Pharm. Sci. 100 9 2011 3731 3750
38. D. Neri, and C.T. Supuran Interfering with pH regulation in tumors as a therapeutic strategy Nat. Rev. Drug. Discov. 10 10 2011 767 777
39. A. Nowack, J. Yao, K.L. Custer, and S.M. Bajjalieh SV2 regulates neurotransmitter release via multiple mechanisms Am. J. Physiol. Cell Physiol. 299 5 2010 C960 C967
40. M. Ohkawa, Y. Ohno, K. Masuko, A. Takeuchi, K. Suda, A. Kubo, R. Kawahara, S. Okazaki, T. Tanaka, H. Saya, M. Seki, T. Enomoto, H. Yagi, Y. Hashimoto, and T. Masuko Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy Biochem. Biophys. Res. Commun. 406 4 2011 649 655
41. L. Peng, W.H. Tepp, E.A. Johnson, and M. Dong Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors PLoS Pathog. 7 3 2011 e1002008
42. M. Pfister, J.M. Whaley, L. Zhang, and J.F. List Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus Clin. Pharmacol. Ther. 89 4 2011 621 625
43. M. Rask-Andersen, M.S. Almen, and H.B. Schioth Trends in the exploitation of novel drug targets Nat. Rev. Drug. Discov. 10 8 2011 579 590
44. T. Sekine, H. Miyazaki, and H. Endou Molecular physiology of renal organic anion transporters Am. J. Physiol. Renal Physiol. 290 2 2006 F251 F261
45. M. Simren, A. Bajor, P.G. Gillberg, M. Rudling, and H. Abrahamsson Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation- A double-blind study Aliment. Pharmacol. Ther. 34 1 2011 41 50
46. S. Sreedharan, J.H. Shaik, P.K. Olszewski, A.S. Levine, H.B. Schioth, and R. Fredriksson Glutamate, aspartate and nucleotide transporters in the SLC17 family form four main phylogenetic clusters: evolution and tissue expression BMC Genomics 11 2010 17
47. V. Vallon, S.A. Eraly, W.R. Wikoff, T. Rieg, G. Kaler, D.M. Truong, S.Y. Ahn, N.R. Mahapatra, S.K. Mahata, J.A. Gangoiti, W. Wu, B.A. Barshop, G. Siuzdak, and S.K. Nigam Organic anion transporter 3 contributes to the regulation of blood pressure J. Am. Soc. Nephrol. 19 9 2008 1732 1740
48. T. Winhusen, E. Somoza, O. Sarid-Segal, R.J. Goldsmith, J.M. Harrer, F.S. Coleman, R. Kahn, S. Osman, J. Mezinskis, S.H. Li, D. Lewis, M. Afshar, D.A. Ciraulo, P. Horn, M.A. Montgomery, and A. Elkashef A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence Drug Alcohol Depend. 91 2-3 2007 205 212
49. Wong, B.S.; Camilleri, M.; McKinzie, S.; Burton, D.; Graffner, H.; Zinsmeister, A.R.; 2011. Effects of A3309, an Ileal Bile Acid Transporter Inhibitor, on Colonic Transit and Symptoms in Females With Functional Constipation. Am. J. Gastroenterol.
50. F.L. Yeh, M. Dong, J. Yao, W.H. Tepp, G. Lin, E.A. Johnson, and E.R. Chapman SV2 mediates entry of tetanus neurotoxin into central neurons PLoS Pathog. 6 11 2010 e1001207